Catalent invests $7.3 million at Aprilia, Italy facility
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it had completed the first phase of a $7.3 million investment to upgrade and expand its packaging and softgel encapsulation capabilities at its facility in Aprilia, Italy.
The first phase of investment, completed in August 2018, saw the expansion and upgrade of the facility’s integrated packaging capabilities, and the commissioning of the first of five new softgel encapsulation lines. The second phase of the investment, to add a further four encapsulation lines, will bring the total number of lines to 23 and significantly expand production, drying, and inspection capacity for nutritional supplements and beauty softgels at the site. It is expected that these four new lines will be fully operational by January 2019.
“We have a long and proud history in softgel product development and commercial manufacturing,” commented Dr. Aris Gennadios, President of Catalent Softgel Technologies. He added, “This investment is driven by increasing demand for nutritional and beauty products globally, and will enable Catalent to better serve these markets.”
Catalent RP Scherer Softgel is a global leader in innovative oral and topical softgel technologies for the pharmaceutical, consumer health, and beauty markets. Its softgel technologies are proven to solve complex bioavailability and formulation challenges, and are preferred in a wide range of consumer health and pharmaceutical product categories. Catalent leverages more than 85 years of experience in softgel formulation, development and manufacturing, as well as its proactively developed products, to help customers bring products to market faster. With a variety of unique, innovative technologies, and highly versatile, most preferred dose forms, Catalent has a wide variety of solutions to meet its customers’ needs.